Name: Patrys (PAB) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

PAB

Pharmaceuticals, Biotechnology & Life Sciences

Patrys

Short interest: 0.00%; −0.01 pp 30d; as of 24 Jan 2025
Reported shorts: 39K
Shares on issue: 2.057B

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Patrys

Development of natural human antibody-based therapies for the treatment of life threatening diseases including cancer.

Company profile →

Patrys (ASX:PAB) has 0.00% of its shares on issue reported as short positions as of 24 Jan 2025, or about 39,007 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.35% in March 2022. PAB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads PAB today

Zanger BreakoutWatchScore 16rank 1426 of 1942
CAN SLIMWatchScore 15rank 943 of 1541
Minervini Trend TemplateWatchScore 12rank 1248 of 1716
Crowded-Short BreakoutNot a candidate
Quality compoundersNot a candidate

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

PAB fundamentals

In the year to 30 Jun 2026, Patrys (ASX:PAB) recorded revenue of A$9.0K and a net loss after tax of A$3.4M. A year earlier it recorded revenue of A$828.5K and a net loss after tax of A$3.0M. Net margin −37,982.1% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 6 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →